
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:CMPS) and Sermo announced on Wednesday findings from a survey of Sermo physician members that showed two-thirds of doctors surveyed believe psilocybin therapy has potential therapeutic benefit for patients with treatment-resistant depression (TRD).
“Severe mental illnesses, such as treatment-resistant depression, have affected too many people in society for too long,” said Murali Doraiswamy MBBS, FRCP, professor of Psychiatry and Behavioural Sciences at Duke University's medical school.